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Abstract 
 
HIV/AIDS virus is spreading and the way to stop it is to do so through different policy 
and legal implementations.  The aim of this thesis is to analyse how ART and international 
finances affect the number of people living with HIV by constructing a correlation matrix 
and regression model. To better analyse how different indicators might be affected 
theoretical overview was given both on medical and political factors. In this thesis three 
hypotheses were formed. Due to the lack of data the first hypotheses (prediction model) 
was rejected and the second hypotheses (descriptive model) was used. The results showed 
that when a number of people living with HIV raises the number of people receiving ART 
and international finances increase. The deduction could be made that implemented 
policies are effective. It is important to note that increasing numbers of HIV cases 
occurred mostly in lower income countries. By analysing political strategies of countries 
it was seen that there was a lack of implementation of human rights even though collective 
rights were mostly covered. As most national government guidelines only included ART, 
HIV testing and counselling. Meaning that due to the lack of implementation of human 
rights, stigma, fear and discrimination amongst key populations are still occurring 
resulting in a number of people not getting tested for HIV. Further research concerning 
how political implementations directly affect the number of people living with HIV is 
needed in order to fully understand the problem and to find the best solution.   
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1. Introduction 
 
According to WHO (World Health Organisation) (2017) at the end of 2016, there were 
36.7 million people living with HIV (Human immunodeficiency virus) and 1.8 million 
people becoming newly infected every year. HIV and AIDS (Acquired 
immunodeficiency syndrome) cause depletion and eventual exhaustion of immune 
responses. HIV often develops into AIDS and in 10 to 15 years or more leads to severe 
disease and death. Since it damages the immune system, there are more infections by 
microorganisms that would normally occur (opportunistic infections or OIs) (Adams and 
Woelk 2014). Between 2000-2016 HIV infections fell by 39% and 13.1 million lives were 
saved (WHO 2017a) and approximately “1 million people died from AIDS-related 
illnesses in 2016” (UNAIDS 2017).  
HIV/AIDS is at a political and social level a major global health problem (pathogenic 
threat), so the governmental approach to the problems of global health and security need 
to be addressed in a broader way (Ingram 2010) since the diseases spread faster and the 
problems of other countries cross borders (Brundtland 2003). By evaluating the 
effectiveness of the HIV programmes countries could improve their capacity to collect 
taxes from their citizens on the more sustainable basis, particularly amongst the middle- 
income countries (Ávila et al. 2013). That could be done by integrating human rights into 
HIV/AIDS programmes. Human rights are influential in framing governmental and 
intergovernmental responses to the pandemic (Meier, Brugh and Halima 2012). 
Costs for ending the HIV/AIDS epidemic by 2020 will increase to US $ 29 million in 
low- and middle-income countries. That involves increasing HIV funding via donors as 
international, and domestic funding is not enough. The main financing goes towards 
revenue rising to pay for HIV interventions and services, financial risk protection and 
pooling (ensuring the continuation of HIV services without financial risks for the 
recipient as well as the provider) and improving efficiency in the use of health system 
resources (WHO 2016a).  
UNAIDS (The Joint United Nations Programme on HIV/AIDS) provides a connection 
between governments and the private sector. Their main strategy is called 90-90-90 
meaning that "by 2020 90% of the people living with HIV know their HIV status, 90% 
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of the diagnosed will receive sustained antiretroviral therapy and 90% of the people 
receiving therapy will have viral suppression" (UNAIDS). 
In less developed countries there are insufficient health systems, and it is difficult to 
implement ART (antiretroviral therapy) which is the most effective mean of controlling 
OIs (opportunistic infections). There are many reasons for this, including the lack of 
medical workers and the higher cost of training them as opposed to other drugs used for 
treating HIV/AIDS.  Key prevention of HIV/AIDS is the targeting of high-risk groups 
as it slows the epidemic from spreading (Adams and Woelk 2014). 
WHO and UNAIDS are the main organisations dealing with HIV/AIDS programmes, 
there is also The Global Fund, which is mainly a financing institution, IAS (International 
Accounting Standards) which provides strategic programmes, initiatives and campaigns, 
USAID, which mainly provides financing, treatment, research on the matter, 
information also strategic coordination and communications, information, evaluation 
and informatics. CDC (Centres for Disease Control and Prevention) and IAPAC 
(International Association of Providers of AIDS Care) are accomplishing their missions 
through a comprehensive program of education, policy and advocacy and also by 
providing direct technical assistance, research and care provision (IAPAC). And there 
is also PEPFAR (The U.S President’s Emergency Plan for AIDS Relief).  
Thesis analyses if and how the number of people living with HIV is affected by 
international finances, ART and how human rights affect different international political 
implementations made. The first part of the thesis consists of a theoretical overview and 
previously conducted analytical researches. The second part of the thesis consists of 
methodology. The third part of the thesis consists of the analysis of data and regression 
model and the relation to previously overviewed theory.  
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2. Theoretical Framework 
 
2.1 Medical overview, ART and treatment of HIV 
 
HIV virus is a retrovirus that infects T-lymphocytes (also called CD4-cells or T-Cells are 
the immune cells which are a subtype of white blood cells) thus causing cytopathic effects 
and harming the lymphatic system (thus immune system) HIV can be categorized into 
HIV-1 and HIV-2, though the first is the most common. (Fauci and Lane 2015). In this 
thesis factors related to HIV-1 are examined.  
HIV is transmitted by unprotected sexual contact (through semen, vaginal and cervical 
secretions), blood or blood products, transplanted tissue, transmission through injection 
drug use (syringes that are contaminated with blood and bodily fluids) and mother to 
infant (intrapartum, perinatally or via breastmilk) (Fauci and Lane 2015; Ahmad, Drew 
and Lagunoff 2018). HIV infection can be categorized into three stages: acute phase (flu-
like symptoms), chronic phase (clinical latency, including the asymptomatic phase where 
the disease is not clinically apparent) and AIDS phase (increasing immunodeficiency and 
more frequently occurring OIs). HIV transmission could be reduced amongst infected 
people by condom usage, circumcision since the infection is facilitated by brakes in 
epithelial surfaces, and also by ART (Ahmad, Drew and Lagunoff 2018). Even 
behavioural approaches like mental health, induced stigma, and fear play a role in 
enhancing the outcome of the treatment (Collier and Sterck 2018). Earlier treatment of 
HIV (T cells count is over 250 cells per µL) is associated with 96% reduction in HIV 
transmission (Fauci and Lane, 2015).   
AMC (adult male circumcision) is often seen as a cost-effective and cost-saving mean for 
prevention of heterosexual acquisition of HIV in men (Uthman et al. 2010) since it is 
reducing HIV transmission. Prevention effectiveness is observed at a biological level 
even though it also is dependent on behavioural indicators (for example cultural 
background affecting decisions concerning circumcision) (Kahn, Marseille and Auvert 
2006). It is important to note that circumcision reduces the risk of acquisition of HIV by 
60% in men and there is not enough evidence approving this theory for transmission to 
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females. Efficiency rates for latex condoms used to prevent HIV transmission 
bidirectionally are up to 98 percent to 99 percent (Ahmad, Drew and Lagunoff 2018). 
Besides the means of prevention, the treatment of HIV is necessary. According to WHO 
“ART refers to the use of a combination of three or more ARV (antiretroviral) drugs 
involving lifelong treatment” (WHO 2017b).  ARV drugs can be categorized into five 
main categories: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), 
Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), 
Entry Inhibitors, Integrase Inhibitors (Flexner). ARV drugs can be further categorised 
into first-line drugs and second-line drugs (Long et al. 2010).  
Since HIV is causing immunodeficiency by harming the lymphatic system, people with 
HIV are more receptive to different diseases. Including leading diseases causing mortality 
among adults and children which are mainly bacterial infections, tuberculosis, 
Pneumocystis jirovecii pneumonia (most common OIs amongst immunocompromised 
hosts). Among children, there are also diarrhoeal diseases, malnutrition and wasting (low 
weight for height) 1.1 million people die from AIDS-related causes (by the data of 2015) 
tuberculosis being the leading cause of morbidity, mortality, and hospitalization among 
people living with HIV. WHO recommended package to reduce mortality and morbidity 
among people with HIV consists: screening, treatment and/ or prophylaxis for major 
opportunistic infections and rapid ART initiation (WHO 2017b).  If not properly treated, 
besides harming the host, some of these infectious diseases could spread faster amongst 
both HIV infected and not infected individuals.  
 
2.2 Financing and international organisations 
 
Per capita, HIV spending varies depending on the income levels and the type of epidemic 
of the country. By evaluating the effectiveness of the HIV programmes countries could 
improve their capacity to collect taxes from their citizens on the more sustainable basis, 
particularly amongst the middle- income countries. Since the expansion of access to HIV 
antiretroviral treatment to 8 million people has resulted in a reduction of HIV related 
deaths by 20 percent in the past five years. But assistance from international organisations 
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is critical since many low-income countries cannot pay the ART needed finances alone 
(Ávila et al. 2013).           
Since primarily international organisations provide finances for ART but the end goal of 
HIV/AIDS epidemic varies by organisations it is important to also asses their main 
strategies to see the mainly financed area. 
PEPFAR strategy for accelerating HIV/AIDS epidemic in 2017-2020 includes, besides 
providing for ART, expansion of HIV prevention and HIV negative risk avoidance 
strategies, expansion of voluntary male circumcision and acceleration of optimized HIV 
testing and treatment strategies.  PEPFAR will support programmes that help to control 
the epidemic in the 13 high-burdened countries: Kenya, Zambia, United Republic of 
Tanzania, Uganda, Zimbabwe, Malawi, Lesotho, Côte d'Ivoire, Botswana, Namibia, 
Swaziland, Haiti and Rwanda (PEPFAR). Meaning that most of the financing will go 
towards ART by supporting the UNAIDS 90-90-90 strategy. US government has invested 
US $70 billion dollars in HIV/AIDS and tuberculosis programs. The US $ 4.3 billion was 
donated to The Global Fund to support the Global Fund's Fifth Voluntary Replenishment 
during the years of 2017-2019 (PEPFAR 2017).  
The UNAIDS  90-90-90 strategy to help to end the AIDS epidemic means that 90% of 
people living with HIV are diagnosed, receive treatment and people receiving ART will 
have viral suppression. Besides treatment for HIV UNAIDS supports flexible health and 
community systems and also protection and promotion of human rights. Core prevention 
strategies include an elimination of mother-to-child transmission, condom programming, 
pre-exposure antiretroviral prophylaxis, voluntary medical male circumcision in priority 
countries, harm reduction services for people who inject drugs and focused prevention 
programming for key populations. (UNAIDS 2014). Key populations include men who 
have sex with men, people who inject drugs, sex workers, transgender people, prisoners, 
children, women and girls, young people and people with disabilities (AVERT).  
All those prevention strategies need increased funding, reaching approximately US$ 18 
billion by 2020 (UNAIDS 2014). WHO shares the 90-90-90 values of UNAIDS but 
ending AIDS epidemic as a public threat by 2030 according to their calculation takes US$ 
26 billion in low- and middle-income countries (WHO 2016a). The Global fund focus on 
HIV is overlapping with the UNAIDS prevention strategies (The Global Fund 2017). 
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Global Fund runs their financing in three-year cycles allocating donor funds to eligible 
countries.  Funding can be submitted separately for HIV, TB (tuberculosis) or malaria or 
as a package for all (The Global Fund).  
It is important to note that although dependant on international financing ART 
programme financing strategies can differ by type of ownership into three categories.     
Private non- profit which sought multiple financial donors to sustain ART interventions. 
Thus being donor-dependent to provide ART without charging patients. Fee approximate 
to $ 1 was charged for every client visit to the clinic. Creating a VIP section to the hospital 
where higher fees were charged allowed to support frequent costs for the wider ART 
programme. Private for-profit hospitals require patients to pay for other costs of HIV care 
and treatment (which is lower than health costs for regular patients) with the exception of 
ARV drugs which are supplied without charge (funded by PEPFAR). Consultation fee 
for HIV patient is approximately $ 4 compared to the regular $ 20 consultation fee. Other 
medical necessities are covered by a medical insurance scheme.  Public facilities sought 
additional funding from private philanthropic organisations and individual donors besides 
funding's from the national government and international organisations. ART financing 
only covers ARV drugs and commodities. Thus to cover other expenses (for example 
costs associated with OIs) health facilities need multiple funding sources to better avoid 
OIs (Zakumumpa, Bennett, and Ssengooba 2017).  
Policies of donors and international organisations bear directly on the evolution of ARV 
markets in low- and middle-income countries. Medicines purchased with funds from UN 
(United Nations), GFATM (Global Fund to Fight AIDS, Tuberculosis, and Malaria) have 
to be pre-qualified by WHO prequel.  In GFATM case drugs could be also qualified by 
US FDA (US Food and Drug Administration), the European Medicines Agency, or 
Health Canada. PEPFAR purchased ARV medicines have to be approved by the standard 
or the tentative FDA approval process.  98% of ARVs purchased in 2004-2006 were listed 
in WHO treatment guidelines. Newly recommended WHO ARVs are at high prices but 
low in demand and manufacture. There are only a few three-in-one Fixed-dose 
combination (FDC) drugs (Waning et al. 2010). Research based on Nigeria's facility-level 
data shows that cost of ART came up to $ 231 USD (on a facility level average). The cost 
was estimated by summing finances for staff, laboratory tests, ARV drugs, TB drugs, 
capital, utilities and training and the staff costs (nurses, doctors, health and indirect staff). 
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ARV drugs making 40 percent of total cost, staff 39 percent and laboratory tests 17 
percent. Some costs could be reduced. For example, lowering staff cost could be done by 
shifting tasks. For example, certain tasks could be shifted from doctors to less specialized 
staff (Bautista-Arredondo et al. 2018). 
 
2.3 HIV as a global political problem  
 
HIV policy in the individual and population level could be divided into three approach 
categories. First behavioural approaches which include education, stigma reduction, 
delay sexual debut, decrease in the number of partners, increased availability and use of 
condoms, harm-reduction strategies (including needle exchange programs). Second 
structural approaches which include law and policy development, gender equity, access 
to services, cash transfer programs, decriminalizing determinants of infection, targeting 
programs and services to MSM (men who have sex with men). Third, biomedical 
approaches, which include testing STIs (sexually transmitted infections), PMCTC, male 
circumcision, antimicrobials/microbicides, PEP (post-exposure prophylaxis), PrEP (pre-
exposure prophylaxis) and treatment as prevention. These preventions are best 
implemented combined to achieve a potentially more cost-effective and sustainable pre-
emptive HIV response (Meier, Brugh and Halima 2012).  But policy implementation at 
the moment is widest in relation to treatment and retention care, and poorer for HIV 
testing and PMTCT. National government guidelines are mostly only about ART, HIV 
testing, PMTCT and counselling (Cawley et al. 2017).  
Integrating human rights into HIV/AIDS programmes could be influential in framing both 
governmental and intergovernmental responses to the pandemic (Meier, Brugh and 
Halima 2012).  Violation of human rights is a continued problem amongst people with 
HIV. Laws and policies need further specifications to protect the human rights of those 
living with HIV and those at risk of HIV infection, especially those who are included in 
the key populations (WHO 2016b). Human rights focus on examining a separated 
individual although having a central role in the global HIV/AIDS programme. Although 
collective rights are similar to human rights, they act more at a social level, addressing 
the problem in a wider spectrum while human rights act on a perspective of an individual. 
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Collective rights, however, are indispensable in the health field. These rights could be 
realized for example through expansion of HIV testing thus preventing the spreading of 
the virus. (Meier, Brugh and Halima 2012). Besides collective rights, one solution could 
be decriminalizing sexual behaviours and drug use, same-sex behaviour and legalizing 
recognition of transgender status.  Since there are difficulties in protecting the safety and 
well-being of these people and also those who provide HIV related health care. In order 
to increase the effectiveness of HIV and HIV related health services reduction of stigma, 
fear and discrimination are needed, especially those related to homophobia, transphobia, 
sex work and drug use is needed. There are also other policy changing methods and law 
enforcement that can help to reduce human and health right discrimination.  For example, 
ensuring confidentiality of medical records. Since for example, same-sex activity is 
banned and being transgender is illegal in some countries many HIV cases are not 
reported (WHO 2016b).   
Besides human rights which have an international impact, it could be argued that national 
policy types could affect the HIV/AIDS pandemic response. Comparative analysis was 
conducted by Gómez and Harris (2015) of AIDS responses in BRICS nations (Brazil, 
Russia, India, China and South Africa) by historical and civil-society dynamics. Results 
show that democracies do not have a better response to epidemics, politically repressive 
regimes might get better numeral outcomes. Effective civil society mobilization is much 
less costly and the engagement can lead to lost opportunities to control or reverse the 
direction of epidemics. In Brazil, influential AIDS NGOs pressured the government for 
a policy reform since there was an absence of political repression and civic mobilization. 
The success of influencing AIDS policies depends on the success of civil society 
organisations, pre-existing political contexts and the state’s historic relationship with civil 
society.  
Even though it could be said that NGOs are important strategic allies for reforming 
policies, in this thesis main focus will be on implementations of human rights, national 
and international policies affecting HIV/AIDS epidemic. 
As mentioned people living with HIV and receiving ART rely mostly on international 
financing to cover the ARV drug costs. These factors are mainly influenced by country’s 
income level, international policy, national policy and integration of collective and human 
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rights. Factors can influence each other both ways. Either by providing more art and 
international finances the changes can be seen in the number of people living with HIV. 
Or when the number of people living with HIV increases the number of people receiving 
ART and international finances invested increase jointly. As human rights could be 
influential in framing international and government policy implementations further 
analysis based on the actions executed by countries is necessary.  
To analyse this problem more specifically three hypotheses are formed.  
First two hypotheses are the variations of possible relationships between people living 
with HIV, people receiving ART and international finances: 
1. As the number of ART and international finances increase the number people 
living with HIV stays at a fairly constant level.  
2. As the number of people living with HIV increases the number of people 
receiving ART and international finances rise.  
Third hypothesis is: 
3. By forming the basis for implemented policies, human rights affect people 
receiving ART and international finances invested.   
 
3. Methodology 
 
Based on the theoretical information, it could only be assumed that when there are more 
ART, national and international finances provided the number of people living with HIV 
should stay constant. As there are more people knowing their HIV status that should lead 
to decrease in infections and spread of the disease as HIV treatment reduces the 
transmission of the virus. To further assess if and how much these relationships are 
affecting each other descriptive models are necessary. 
A dataset was constructed by using World Bank division of countries by income levels 
(low-income economies; lower-middle-income economies; upper-middle-income 
economies and high-income economies).  Data was defined by a 2008-2016 time interval 
(factor value).  
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Used data included The World Bank development indicators (The World Bank): 
• Adults (ages 15+) living with HIV 
• Adults (ages 15+) and children (ages 0-14) newly infected with HIV 
• AIDS estimated deaths (UNAIDS estimates) 
• Current health expenditure per capita (current US$) 
• Antiretroviral therapy coverage (ART) (out of the number of people living with 
HIV)	 
And an added indicator: 
• International finances provided to the countries based on the domestic HIV 
spending by funding source	(UNAIDS data 2015)		
Data were divided into dependent variable and independent variables. 
To examine the effectiveness of international organisations a dependent variable of adults 
(ages 15+) living with HIV was chosen.  
To assess the international organisation’s actions effectiveness independent variables 
chosen were:  
•  Current health expenditure per capita  
•  ART  
•  International finances 
Missing data of international finances by year was replaced by the data of years available. 
Due to the lack of information in indicators, some countries were excluded. Which left 
50 countries to the final dataset based on the availability of data.  
Following countries were chosen:  
• Fourteen low-income: Burundi, Chad, Ethiopia, Haiti, Liberia, Malawi, Mali, 
Mozambique, Nepal, Nigeria, South Africa, Togo, Uganda and Zimbabwe. 
• Twenty lower-middle-income: Angola, Burkina Faso, Cambodia, Cameroon, 
Côte d'Ivoire, El Salvador, Ghana, Guatemala, Honduras, India, Indonesia, 
Kenya, Lesotho, Myanmar, Niger, Sudan, Swaziland, Ukraine, Vietnam and 
Zambia. 
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• Fourteen upper-middle-income: Argentina, Botswana, Brazil, Columbia, 
Dominican Republic, Gabon, Iran (Islamic Republic), Malaysia, Mexico, 
Namibia, Papua New Guinea, Rwanda, Thailand and Venezuela (RB).  
• Two high-income: Pakistan and Senegal.	 
Baseline data is added to Annex 1.  
To verify the accuracy of the models and to identify the unusual observations several tests 
were made to test both hypotheses. Tests included VIF (variance inflation factor), 
Shapiro-Wilk test (test for normality) and Breush-Pagan test (heteroskedasticity test). 
The first two hypotheses were analysed with the correlation matrix and the regression 
analysis. First hypothesis is predictive and the second hypothesis is descriptive. 
Sprearman’s correlation matrix was conducted in order to see the measured strength and 
the direction between two variables. Correlation above + 0,4 and -0,4 was considered a 
strong correlation.  Due to multicollinearity correlations larger than 0,9 were left out.  
Variables excluded from the matrix for both hypotheses due to multicollinearity were: 
•  AIDS estimated deaths (UNAIDS estimates) 
•  Adults (ages 15+) and children (ages 0-14) newly infected with HIV 
Variable excluded due to low correlation (-0,08) was:  
• Current health expenditure per capita (current US$)  
Final models consisted of the dependent variable living with HIV and two independent 
variables. Income was used as a dummy variable on both cases.  
For the regression model data validity is first examined by Spearman’s correlation. A 
best-fit model was chosen by analysing different dependent variable relations to 
independent variables. Evaluating the fit of the model R-squared was measured with 
adjusted R-squared and Root MSE (root-mean-square-error) showing the fit and the 
variance of the residual in these models between the values.   
First two hypotheses were both analysed by correlation and regression. The hypotheses 
with the lowest accuracy was excluded. 
Statistical analyses were performed by using STATA software version 13.0.  
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By analysing the strength of the first hypothesis stated with correlation matrix and 
regression model it appeared that the fit and the significance outcome were not 
statistically important. Which might have been due to limited data. Hypothesis two had 
the best fit to the model.  Since the predictive model was not possible with the final dataset 
instead a pilot study was conducted by using a descriptive analysis.  
Hypothesis chosen was: 
1. As the number of people living with HIV increases the number of people receiving 
ART and international finances rise.  
R-squared value was 0,67 which implies that the strength of relationships between 
variables is strong. Significance level between variables was indicated by p<0,5. 
 
4. Analysis and discussion 
 
The first part will focus on the interpretation of the correlation matrix and the regression 
analysis made on the first hypotheses. The second part will analyse how ART and 
international financing affect the number of people living with HIV. The second part will 
focus more on the political implementations and human rights relating to indicators 
discussed in the first part.  
 
4.1 Interpretation of the correlation matrix and the regression analysis 
 
 
Table 1 
Correlation between people living with HIV, people receiving ART and 
international finances invested 
 
 Living with  
HIV 
ART International 
finance 
Year  
ART 0.7728     
International 
finance 
0.4602 0.4791    
Income -0.2086 -0.0756 -0.1007 -0.0284  
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Correlation matrix consists of dependent variable living with HIV and two independent 
variables (people receiving ART and intfinance) which had the best fit (table 1.). Most 
people living with HIV receive ART since the significance level is at 0,7728 (heavily 
correlated). International financing for ART is moderately correlated at the level of 
0,4602. Correlation between variables is positive. Meaning when the number of people 
living with HIV increases both independent variables increase. Countries income level 
has a lower significance to the number of people living with HIV. Correlation between 
variables is negative. Meaning that when the number of people living with HIV increases 
independent variable decreases.  
 
Table 2 
Relationship of people living with HIV on people receiving ART and international 
financing 
 
Living with 
HIV 
Coefficient 
Standard 
Error 
t-statistic P>| t | 
95% Confidence  
Intervals for 
coefficients 
ART 3.328456 .2205595 15.09 0.000 2.893382 3.763531 
International 
finance 
.0004412 .0001488 2.97 0.003 .0001477 .0007346 
Income -97001.31 28348.19 -3.42 0.001 -152920.8 -41081.81 
The significance level is indicated by p<0,5 
 
Linear multiple regression was chosen to model relations between variables (Table 2). 
When looking at the model we are interpreting it as two populations where second has a 
one value increase in the number of people living with HIV. When the number of people 
living with HIV increases by 1 ART increases approximately 3 times. Meaning that for 
every patient with HIV they receive significant treatment as the minimum rise per person 
for basic treatment would be 1. For every unit increase in the number of people living 
with HIV income decreases. Meaning that there are more people living with HIV amongst 
the lower income countries. When looking at the coefficient for the international finances 
it might seem small due to the larger baseline data but is still significant in the model. 
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The international finance units increase by 0.004 when the number of people living with 
HIV increases by 1.  
Based on these two models it could be said that when the number of people living with 
HIV raises the number of people receiving ART and international finances increases. It 
is also important to note that increasing numbers of HIV cases occur mostly in lower 
income countries. As the country’s income level increases the number of people living 
with HIV decreases.  
 
 
4.2 The impact of ART and international financing on the number of 
people living with HIV  
 
As shown in the regression model and correlation matrix demonstrated when the number 
of people living with HIV increases the number of ART and international finance increase 
as well. Showing that implemented policies could be effective as they are increasing 
jointly.  As the level of income increases the number of people living with HIV decreases.  
What was not expected was that national health expenditure per capita would not impact 
the model. One explanation for low impact of national health expenditure might be that 
ART financing only covers ARV drugs and commodities (Zakumumpa, Bennett, and 
Ssengooba. 2017). ARV drugs, however, make up 40 percent of total cost of ART 
(Bautista-Arredondo et al. 2018) and estimated mean cost for per-person for a year is 
$315. Cost per-person differentiates whether the patient comes from a low and lower-
middle-income country or upper-middle-income country. Cost per-person is respectively 
$442 and $80 (PEPFAR 2014). The highest number of people living with HIV occur 
(based on data presented in Annex 1) amongst low and lower-middle-income countries. 
First being South Africa with 6800000 and following in descending order: Nigeria, India, 
Mozambique, Kenya, Uganda, Zimbabwe, Uganda, Zambia, Malawi. These are the ten 
countries with the highest number of people living with HIV and they all are low and 
lower-middle-income countries. Since ARV drugs are costlier and covered by 
international finance the HIV treatment financed by national health expenditure has a 
lower impact.  
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The reason, why the price is higher for low and lower-middle-income countries, could be 
explained by the type of ARV drugs used. Namely, the cost of second-line therapy (using 
second-line drugs) is approximately 2.4 times higher than for the first-line therapy (using 
first-line drugs) (Long et al. 2010).  Lower prices for both second-line and first-line ARV 
drugs were associated with having an essential medicines list and price regulations. 
Higher prices were only significant for second-line ARV drugs with national procurement 
strategies Second-line ARV drugs might reflect higher medical need due to potential 
resistance or adverse effects of first-line drugs, which are most commonly used. (Liu and 
Galarraga 2017). 
The problem of corruption might have an effect on ARV drug prices. Unitaid and 
PEPFAR have contracted two or three manufacturers thus the chosen manufacturers to 
dominate the market (Waning et al. 2010). When international organizations with a wide 
impact choose a few manufacturers the ARV drug prices get higher since there is no 
competition that comes with the free market system. GFTAM Voluntary Pooled 
Procurement (VPP) program will encourage the pooling of ARV volumes through third-
party provision by introducing more large-scale buyers.  Meaning that the market will 
now be concentrated around few large-scale purchasers increasing prices and corruption. 
Pooled provision might be attractive to governments of smaller countries as a way to 
reduce transactions costs and documented corruption. But in reality, the costs may not be 
lower (Waning et al. 2010).  
Lower ARV prices are possible but continued innovation and quality must also be ensured 
for the drugs to be effective. A narrow focus on price alone might not be efficient in the 
terms of ART outcome (Waning et al. 2010). The staff makes up for 39 percent and 
laboratory tests for 17 percent of total ART costs (Bautista-Arredondo et al. 2018).  One 
way of reducing these costs for ART and increase the uptake of HIV testing services is 
to use trained lay providers to perform HIV rapid tests using finger stick blood, oral fluids 
and pre and post-test counselling thus task-sharing and lowering the workload of medical 
workers (Flynn et al. 2017).   
Lowering the cost of ART (especially for low and low-middle-income countries) could 
be possible through implementing HIV prevention strategies. For example, by AMC 
(adult male circumcision). AMC is seen as a cost-effective and cost-saving mean for 
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prevention of heterosexual acquisition of HIV in men (Uthman et al. 2010) since it is 
reducing HIV transmission. But at the same time efficiency rates for latex condoms used 
to prevent HIV transmission bidirectionally are up to 98 percent to 99 percent (Ahmad, 
Drew and Lagunoff 2018). As well as lower in cost, since AMC is more time and finance 
consuming. AMC in combination with latex condoms would have a high effectiveness 
rate. But it must be considered that AMC is not as cost-effective as latex condoms since 
it takes more healthcare finances.  
 
4.3 The impact of political and human right implementations on the 
ART, international finances and number of people living with HIV  
 
Although the number of ART per person described in the model is high there is still room 
for improvement as. Even though it could be said that due to the rise in ART and finances 
with the number of people living with the implemented policies must be effective. It must 
be noted that people in the model have been diagnosed with HIV there is still a number 
of people undiagnosed due to multiple reasons like stigma, fear and discrimination. That 
is why it is also important to promote different policies, collective and human rights to 
reduce stigma and for more people to get tested for HIV thus reducing the risk of infection 
spreading.  
Since the duty to rescue people with HIV is moral minimalism it is convenient for 
policymaking in democracy (Collier and Sterck 2018). When analysing the international 
finances and political implementations we must consider that even though not directly 
measured, different policies implemented affect the indicators related to people living 
with HIV, ART and international finances given to countries. To better analyse the 
HIV/AIDS-related policy implementations HIV/AIDS country progress reports are used 
since direct approach by the country is best shown. Example countries are apparent in the 
correlation model (table 1.) and regression model (table 2.). 
Botswana, for example, has adopted by the year 2016 different UNAIDS 90-90-90 related 
targets, including for example development of the HIV testing services. Also being in the 
process of improving the distribution of HIV test kits across districts and launching new 
guidelines and plans. The country is also planning to adopt lay provider testing. Even 
	 23	
though there are still problems in the discriminatory areas, national strategies, 
discriminatory and punitive laws for protecting people living with HIV and vulnerable 
populations are at work. Right now the country is lacking in prevention strategies 
(National AIDS Coordinating Agency Ministry of Ministry of Health and Wellness 
Botswana 2017).  
Burundi has partly regulated laws and policy’s specifying for HIV testing. But when 
looking at key populations transgender people and sex workers are still criminalized and 
prosecuted (Country progress report-Burundi 2017). Colombia and Kenya have both 
implemented legal protections for key populations by constitutional prohibition of 
discrimination based on occupation or diversity amongst transgender people and sex 
workers (Country progress report-Colombia 2017: Country progress report-Kenya 2017).       
In Kenya selling and buying sexual services is criminalized and men who have sex with 
men face imprisonment up to 14 years (Country progress report-Kenya 2017). Nepal has 
made targeted interventions amongst HIV key populations by improving HIV testing and 
prevention policies. For example, testing and counselling for HIV care and support, 
reproductive health and sexually transmitted infections.  They have also implemented the 
identification of the existence of “gender and sexual minorities” in its constitution 
(Government of Nepal Ministry of Health National Centre for AIDS and STD Control)  
Ukraine has transferred procurement for ARVs and laboratory commodities to 
international agencies as an anticorruption measure and as a response to stagnation in the 
national procurement capacity (Global AIDS Monitoring 2017: Ukraine).  
By analysing political strategies of countries which are included in the baseline data it 
can be seen that there is a lack of implementation of human rights. Collective rights are 
better implemented as they are easily realized for example through expansion of HIV 
testing as was seen amongst Burundi and Nepal.  Violation of human rights is a continued 
problem as seen from regulations of laws for HIV key populations. And even though 
when some key populations were legalized some still criminalized.  Meaning that the key 
population might not get tested for the reasons mentioned above that could result in a 
significant number of people not getting tested for HIV.  
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It must be noted that the data for most countries was not sufficient for more precise 
deductions. For many countries, specific regulations and policies were missing and 
reports were more focused on the medical part and situation analysis.  
 
5. Conclusion  
 
Earlier treatment of HIV (T cells count is over 250 cells per µL) is associated with 96% 
reduction in HIV transmission (Fauci and Lane 2015). Reaching the 90-90-90 strategy to 
help to end the AIDS epidemic means that 90% of people living with HIV are diagnosed, 
receive treatment and people receiving ART will have viral suppression. For that more 
cost-effective means are needed, and finances need to be better divided. ARV drugs right 
now make 40 percent of the total cost leaving very little to the other health services 
financing. And even though some means are claimed to be more cost effective (for 
example AMC) in the long run when including the finances, it might not be so in reality. 
To further assess if and how much these relationships are affecting each other descriptive 
models were created. As human rights could be influential in framing international and 
government policy implementations they were included in the analysis.  
Three hypotheses were formed. The first stating that as the number of ART and 
international finances increase the number people living with HIV stays at a fairly 
constant level. The second stating that as the number of people living with HIV increases 
the number of ART provided and international finances invested raise. The third 
hypothesis stating that by forming the basis for implemented policies, human rights affect 
people receiving ART and international finances invested. The chosen variables were, 
dependent variable-people living with HIV, and independent variables people receiving 
ART and international finances. Data were examined by Sprearman’s correlation matrix 
and the regression model. Due to the lack of data the first hypothesis of ART and 
international finances invested affecting the number of people living with HIV was not 
used. The second hypothesis was better confirmed by the correlation matrix and 
regression model. It was also found that as the country’s income level increases the 
number of people living with HIV decreases.  
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Even though ART and international finances increasing jointly with the number of people 
living with HIV could implement that the implied policies are effective. It is also 
important to note that there might still be a significant number of people not tested. Thus 
the importance of integrating human rights into HIV/AIDS programmes is influential in 
framing governmental and intergovernmental responses to the pandemic. 
Country progress reports on HIV/AIDS progress of countries appearing in the baseline 
statistical data were made as an example of policy and human rights implementations. It 
was seen that there was a lack of implementation of human rights. Collective rights were 
better implemented as they are easily realized through the expansion of HIV testing 
Violation of human rights was a continued problem as seen from regulations and laws for 
HIV key populations. Some key populations were legalized others still criminalised. To 
reduce fear, stigma and discrimination and for more people to get tested for HIV wider 
implementation of human rights is necessary. Right now most national government 
guidelines only include ART and HIV testing. 
More precise political implementations are necessary to see a greater effect on the people 
living with HIV, ART and financing. It was noted that in many cases country progress 
reports were missing data and examples of policies implemented. Lacunal data on the 
topic is leaving unexplained reasons how and what is precisely more affecting the number 
of people living with HIV.   
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Rahvusvaheliste organisatsioonide mõju võitluses HIV/AIDS-iga 
 
Kerstin-Gertrud Kärblane 
 
Resümee 
HIV viirushaigusesse haigestunute arv suureneb iga aastaga umbes 1,8 miljoni võrra. 
HIV/AIDS nõrgestab inimese immuunsüsteemi, põhjustades lisaks olemasolevale 
viirusele, mitmete teise nakkushaigustega nakatumist. Kuna haiguse levik on kiire ning 
oht on globaalne siis osutub see ka  probleemiks rahvusvaheliselt. Haiguse raviks 
kasutatakse hetkel ART ehk retroviiruse vastast ravi, mis hõlmab endas ravimeid ning 
erinevaid haigusega seonduvaid protsesse (erinevad meditsiinilised testid, 
konsultatsioonid jne). Haigusega seostuvad poliitilised ja inimõiguste teemalised 
probleemid vajavad paremat  ja täpsemat käsitlust, et vähendada HIV nakatunute arvu.  
Mida tervem on rahvas seda rohkem saab riik pidevat maksutulu oma kodanikelt.   
Erinevateks ennetavateks võimalusteks on panustada hariduspoliitikasse, õigusloomesse, 
kaitsmaks nakatunute ning peamises riskigrupis olevaid inimesi ning 
biomeditsiinilistesse meetmetesse. Peamisesse riskigruppi kuuluvad inimesed, kelle 
õigused on piiratud mitmetes riikides ning kes oma tegevustega osutuvad nakkusele 
kergemini vastuvõtlikuks. Näiteks homoseksuaalid, narkootikume süstivad inimesed 
ning prostitutsiooniga tegelevad inimesed.  
Peamised organisatsioonid, kes tegelevad HIV/AIDSI ennetamise ning ravi 
programmidega, on PEPFAR, UNAIDS ning WHO. Rahvusvaheliste organisatsioonide 
poliitilised otsused mängivad olulist rolli ravi kujunemisel ning ravimite hindades. Enne 
erinevate ravimite ostmist peavad need olema ka teiste organisatsioonide poolt 
kontrollitud, kuid peamiselt ostetakse ravimeid, mis on loetletud WHO ravijuhendis.  Ka 
inimõiguste integreerimine HIV programmidesse on oluline, kuna HIV nakatunute ning 
riskigruppi kuuluvate inimeste õigused ei ole sageli tagatud. Seega on  erinevate 
stigmade, hirmude ning diskrimineerimise vähendamine oluline, et kõik inimesed saaksid 
paremamaid teenuseid seoses haiguse tuvastamisega ning  raviga.   
	 27	
Seega võib oletada, et lisaks ART-i ning rahvusvahelisele rahastusele mõjutab HIV-ga 
elavaid inimesi ka riigi oma rahastus tervisesektoris. 
Töö käigus püstitati kolm hüpoteesi. Esimene hindas rahvusvahelise rahastuse ja ART 
mõju HIV-ga elavate inimeste arvule (ennustav mudel) Teine hüpotees hindas HIV-ga 
elavate inimese kasvuga koos suurenevat rahvusvahelist rahastust ning ART ravi (piloot 
uuring). Kolmandaks, poliitilised ning inimõigustega seonduvad meetmeid mõjutavad 
rahvusvahelist rahastust ning saadavat ravi (ART). 
Kahe esimese hüpoteesi mõju täpsemaks hindamiseks teostati korrelatsioon- ja 
regressioonanalüüs. Algsesse valimisse kuulusid: HIV-ga elavad inimesed, 
rahvusvaheline rahastus, riigipõhine tervise rahastus, AIDS-i surmad ning HIV-iga 
nakatunute arv. Vaadeldavad riigid valiti sissetulekute tasemete järgi (madala 
sissetulekuga, madala keskmise sissetulekuga, kõrge keskmise sissetulekuga ning kõrge 
sissetulekuga). Andmete puudusel eemaldati valimist riike ning alles jäi 50 riiki. Kuna 
valim polnud piisav ennustavaks mudeliks teostati pilootuuring. 50 riigiga teostatud 
analüüsidest järeldus, et peamiselt mõjutab HIV-ga elavaid inimesi ART  ja 
rahvusvaheline rahastus. Seega HIV-ga nakatunud inimesed sõltuvad suuresti oma ravis 
rahvusvaheliste organisatsioonide rahastusest. Riigi oma rahastus ning teised näitajad ei 
omanud suurt mõju mudelis HIV-ga elavatele inimestele. ART kasv koos inimestega kes 
elavad HIV-iga oli oluliselt suur, millest võib järeldada, et rakendatavad poliitikad on 
olnud edukad. Märkida tuleb, et mudel ei kaasa inimesi kellel pole diagnoositud HIV-d 
seega on vajalikud edasised meetmete rakendused keskendumaks inimeste testimisele 
vähendamaks viiruse nakkusohtlikuks. Mida rohkem inimesi teab oma HIV haigusest 
ning saab ravi seda väiksem on tõenäosus edasikandumiseks.  
Saavutamaks UNAIDSI 90-90-90 strateegiat, kus 90 protsenti inimestest on diagnoositud 
ning saavad ravi on vaja siiski lisaks rahvusvahelisele rahastusele ka suuremat riigi 
omapoolset panust vältimaks uusi haigusjuhtumeid. Vajalikud oleks täpsemad uuringud, 
et paremini hinnata, kuidas tehtavad poliitilised otsused mõjutavad HIV-ga elavaid 
inimesi ning nende ravi. 
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Annex 1 
Country (low income) Year Newly infected 
Health 
expenditure AIDS deaths Living with HIV INT finance ART 
Burundi 2008 4000 184239192 7800 83000 20204374 12450 
Burundi 2009 4400 2204855877 7100 80000 24950075 15200 
Burundi 2010 4400 2613816583 6400 78000 39908205 19500 
Burundi 2011 4200 2577428698 5500 76000 23408823 22040 
Burundi 2012 3900 2162524176 4800 75000 36476780 24750 
Burundi 2013 3500 2203444551 4300 74000 39481263 27380 
Burundi 2014 3200 2020157561 4100 73000 0 31390 
Burundi 2015 2600 2428560168 3500 72000 0 36000 
Burundi 2016 2200 0 2900 72000 0 43920 
Chad 2008 7200 3788076904 5600 90000 11652559 16200 
Chad 2009 6500 3586364862 4000 92000 10463370 22080 
Chad 2010 6200 3648620983 3600 94000 7929254 28200 
Chad 2011 6000 3872567404 3600 95000 15164149 28500 
Chad 2012 5900 3492486746 4000 96000 9884338 31680 
Chad 2013 5500 4742296057 4000 97000 12886293 34920 
Chad 2014 5800 4688535547 4200 98000 0 43120 
Chad 2015 5000 3556909713 3600 100000 0 54000 
Chad 2016 4800 0 2800 100000 0 39000 
Ethiopia 2008 22000 1340835723 57000 650000 210000000 110500 
Ethiopia 2009 22000 1480748258 47000 630000 0 151200 
Ethiopia 2010 23000 1679140775 39000 610000 0 189100 
Ethiopia 2011 24000 1526548301 32000 610000 350000000 225700 
Ethiopia 2012 25000 2087776231 26000 610000 0 250100 
Ethiopia 2013 27000 2007690426 25000 620000 0 279000 
Ethiopia 2014 28000 2250598448 24000 630000 0 327600 
Ethiopia 2015 30000 2427819125 22000 640000 0 352000 
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Ethiopia 2016 30000 0 20000 650000 0 383500 
Haiti 2008 11000 5055632226 7400 130000 140000000 19500 
Haiti 2009 11000 573187032 6500 130000 130000000 24700 
Haiti 2010 11000 6853236416 6100 130000 160000000 27300 
Haiti 2011 10000 7837832202 6400 130000 210000000 31200 
Haiti 2012 9500 7668530846 6200 140000 0 42000 
Haiti 2013 9000 5819069094 5700 140000 0 51800 
Haiti 2014 8700 5895661459 5100 140000 0 58800 
Haiti 2015 8300 5357394448 4800 140000 0 64400 
Haiti 2016 7900 0 4600 150000 0 82500 
Liberia 2008 2300 2559430642 4400 43000 0 1720 
Liberia 2009 2400 3208361643 4200 42000 0 2520 
Liberia 2010 2400 3267554342 3900 40000 28274595 4000 
Liberia 2011 2500 3997556887 3500 39000 30933572 5070 
Liberia 2012 2700 385291602 3200 39000 0 4680 
Liberia 2013 3000 4162495422 3000 39000 0 5850 
Liberia 2014 3100 6463458129 2900 39000 0 6240 
Liberia 2015 3000 6929014961 2900 39000 0 6630 
Liberia 2016 2900 0 2800 39000 0 7410 
Malawi 2008 64000 3205834745 57000 800000 100000000 128000 
Malawi 2009 61000 3479434998 51000 810000 71804797 170100 
Malawi 2010 59000 3322835282 45000 820000 65560000 213200 
Malawi 2011 54000 3838077056 41000 840000 77390000 277200 
Malawi 2012 49000 3175400262 37000 850000 0 348500 
Malawi 2013 45000 3854927575 32000 870000 0 408900 
Malawi 2014 42000 3441162976 28000 880000 0 466400 
Malawi 2015 39000 3422346802 26000 900000 0 522000 
Malawi 2016 36000 0 24000 920000 0 607200 
Mali 2008 7900 3314415863 6100 100000 35990239 15000 
Mali 2009 7200 3273189198 5700 100000 22879948 19000 
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Mali 2010 6600 313685016 5500 100000 30015865 22000 
Mali 2011 6300 3424137183 5200 100000 17896310 26000 
Mali 2012 6300 3422156377 4800 99000 15450592 24750 
Mali 2013 6600 42195893 5300 99000 0 24750 
Mali 2014 6400 4785089271 6200 98000 0 27440 
Mali 2015 6100 4229922694 6400 97000 0 31040 
Mali 2016 5900 0 6100 96000 0 33600 
Mozambique 2008 160000 2321998061 81000 1400000 140000000 126000 
Mozambique 2009 150000 2301493027 79000 1500000 0 150000 
Mozambique 2010 150000 2145723117 81000 1500000 0 195000 
Mozambique 2011 150000 2335510693 82000 1500000 250000000 240000 
Mozambique 2012 140000 3060811274 83000 1600000 0 272000 
Mozambique 2013 120000 2846995455 84000 1600000 0 432000 
Mozambique 2014 100000 3444261128 79000 1600000 0 560000 
Mozambique 2015 95000 2829781169 70000 1600000 0 704000 
Mozambique 2016 83000 0 62000 1600000 0 864000 
Nepal 2008 3000 1923009454 2600 38000 0 2280 
Nepal 2009 2400 2120324868 2500 37000 19713138 3330 
Nepal 2010 2200 299717974 2500 37000 0 4810 
Nepal 2011 2000 34319381 2400 36000 0 6120 
Nepal 2012 1700 3350667901 2300 35000 0 7350 
Nepal 2013 1500 3699805929 2200 34000 0 8500 
Nepal 2014 1300 4138941043 2100 33000 0 9900 
Nepal 2015 1100 444173729 1900 32000 0 11520 
Nepal 2016 1000 0 1700 31000 0 12400 
Nigeria 2008 230000 8143559997 210000 2900000 360000000 232000 
Nigeria 2009 230000 6791492142 200000 2800000 320000000 280000 
Nigeria 2010 230000 7607782636 200000 2800000 370000000 308000 
Nigeria 2011 230000 8393624495 210000 2800000 410000000 364000 
Nigeria 2012 220000 916303815 200000 2800000 440000000 448000 
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Nigeria 2013 220000 10176868861 190000 2800000 0 588000 
Nigeria 2014 210000 10731129835 170000 2900000 0 667000 
Nigeria 2015 220000 9730686106 160000 2900000 0 754000 
Nigeria 2016 220000 0 160000 2900000 0 870000 
South Africa 2008 450000 3723551131 260000 5400000 0 540000 
South Africa 2009 410000 4130740827 240000 5500000 270000000 825000 
South Africa 2010 380000 53956761477 210000 5700000 0 1140000 
South Africa 2011 350000 59735944784 190000 5900000 0 1593000 
South Africa 2012 340000 57974856297 150000 6000000 0 2040000 
South Africa 2013 320000 52649957517 130000 6200000 0 2480000 
South Africa 2014 300000 50983326095 110000 6400000 0 2880000 
South Africa 2015 290000 47079699332 110000 6600000 0 3234000 
South Africa 2016 270000 0 110000 6800000 0 3808000 
Togo 2008 6200 2366442061 8600 100000 14292840 9000 
Togo 2009 5900 2614805602 8400 100000 11421701 14000 
Togo 2010 5500 3093862791 7600 98000 13512726 18620 
Togo 2011 4800 3460344691 6700 95000 16113033 21850 
Togo 2012 4700 3450712886 6300 93000 12328341 23250 
Togo 2013 4600 3828368022 5900 92000 0 27600 
Togo 2014 4500 4011070061 5900 90000 0 30600 
Togo 2015 4100 3664787882 5600 89000 0 34710 
Togo 2016 4100 0 5100 88000 0 44880 
Uganda 2008 100000 5134829778 76000 1000000 260000000 130000 
Uganda 2009 110000 4846931386 69000 1100000 0 176000 
Uganda 2010 99000 6266848192 63000 1100000 0 220000 
Uganda 2011 94000 536802174 57000 1100000 0 264000 
Uganda 2012 84000 5327356031 52000 1200000 0 396000 
Uganda 2013 74000 4963246481 43000 1200000 0 528000 
Uganda 2014 60000 5290539519 36000 1200000 0 660000 
Uganda 2015 54000 4605846472 31000 1200000 0 720000 
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Uganda 2016 52000 0 28000 1300000 0 871000 
Zimbabwe 2008 85000 0 80000 1200000 26989448 144000 
Zimbabwe 2009 83000 0 71000 1200000 61552177 216000 
Zimbabwe 2010 73000 7763721647 59000 1200000 160000000 348000 
Zimbabwe 2011 66000 7114893849 47000 1200000 170000000 456000 
Zimbabwe 2012 59000 6998601317 41000 1200000 220000000 528000 
Zimbabwe 2013 55000 6878401188 37000 1200000 220000000 624000 
Zimbabwe 2014 49000 8185889165 33000 1200000 0 732000 
Zimbabwe 2015 44000 9429000594 31000 1200000 0 816000 
Zimbabwe 2016 40000 0 30000 1200000 0 900000 
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Health 
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Angola 2008 23000 13537606862 8600 170000 7687283 11900 
Angola 2009 24000 12000439409 9000 180000 18379174 16200 
Angola 2010 25000 967489729 9400 190000 18187724 20900 
Angola 2011 26000 12222687671 9900 200000 12015142 24000 
Angola 2012 26000 12248093963 11000 210000 0 27300 
Angola 2013 26000 14378773001 11000 230000 0 39100 
Angola 2014 25000 13184200753 11000 240000 0 50400 
Angola 2015 25000 10855953548 11000 250000 0 57500 
Angola 2016 25000 0 11000 260000 1976746015 57200 
Burkina Faso 2008 4100 2978364972 7600 86000 35887066 17200 
Burkina Faso 2009 3900 3159088375 6400 84000 35828848 21840 
Burkina Faso 2010 3900 3391081732 5700 83000 38997892 25730 
Burkina Faso 2011 3900 3468530369 4900 83000 27524274 30710 
Burkina Faso 2012 3800 3297102135 4100 83000 22348665 32370 
Burkina Faso 2013 3900 4301057125 4200 83000 0 35690 
Burkina Faso 2014 3700 3955127795 4200 83000 0 39840 
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Burkina Faso 2015 3400 3344341877 3700 84000 0 46200 
Burkina Faso 2016 3400 0 3100 84000 0 50400 
Cambodia 2008 2300 4923015402 3300 78000 46585415 29640 
Cambodia 2009 2000 5598244138 2800 77000 51994840 35420 
Cambodia 2010 1600 5445417894 2600 75000 55571098 39750 
Cambodia 2011 1300 6621792342 2500 74000 46569946 43660 
Cambodia 2012 1200 6906166782 2500 73000 44713950 45990 
Cambodia 2013 1000 7008952996 2400 71000 0 47570 
Cambodia 2014 1000 6786517096 2300 69000 0 48990 
Cambodia 2015 1000 695850378 2000 68000 0 51680 
Cambodia 2016 1000 0 1800 67000 0 53600 
Cameroon 2008 42000 6145114496 28000 500000 32949334 55000 
Cameroon 2009 39000 5796943368 28000 510000 63401167 71400 
Cameroon 2010 36000 5896177642 27000 510000 40916286 81600 
Cameroon 2011 35000 4859146001 28000 510000 34159215 96900 
Cameroon 2012 34000 6270305079 28000 520000 30513008 114400 
Cameroon 2013 33000 6726609211 29000 520000 0 119600 
Cameroon 2014 33000 7124243367 31000 520000 0 135200 
Cameroon 2015 31000 6362799174 31000 510000 0 153000 
Cameroon 2016 32000 0 29000 510000 0 188700 
Côte d'Ivoire 2008 25000 760630344 31000 500000 56776965 90000 
Côte d'Ivoire 2009 27000 757871072 31000 490000 120000000 78400 
Côte d'Ivoire 2010 25000 7497885684 29000 480000 110000000 76800 
Côte d'Ivoire 2011 24000 7344966459 26000 470000 87632863 89300 
Côte d'Ivoire 2012 24000 7529444006 29000 460000 0 101200 
Côte d'Ivoire 2013 23000 7223057388 30000 450000 0 99000 
Côte d'Ivoire 2014 22000 7905314337 31000 440000 0 127600 
Côte d'Ivoire 2015 21000 7545261707 29000 430000 0 146200 
Côte d'Ivoire 2016 20000 0 25000 420000 0 172200 
El Salvador 2008 1500 21794343683 1000 22000 7953330 5720 
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El Salvador 2009 1500 22995543951 1000 22000 0 7040 
El Salvador 2010 1400 24024166267 1000 22000 11455432 8140 
El Salvador 2011 1300 25434715207 1000 23000 0 8740 
El Salvador 2012 1200 25660454513 1000 23000 13976689 8970 
El Salvador 2013 1100 26953929088 1000 23000 13764792 9890 
El Salvador 2014 1100 27109835415 1000 23000 0 10120 
El Salvador 2015 1000 28315663041 1000 23000 0 10350 
El Salvador 2016 1000 0 1000 23000 0 11040 
Ghana 2008 16000 7844189486 30000 290000 32588547 20300 
Ghana 2009 16000 7070895365 27000 270000 40544315 27000 
Ghana 2010 17000 8554368917 25000 260000 48015481 33800 
Ghana 2011 17000 9592606699 22000 260000 60807945 52000 
Ghana 2012 17000 8899614253 19000 250000 0 60000 
Ghana 2013 18000 10462707984 18000 250000 0 65000 
Ghana 2014 19000 7675251824 17000 250000 0 72500 
Ghana 2015 20000 795882796 16000 260000 0 72800 
Ghana 2016 20000 0 15000 260000 0 88400 
Guatemala 2008 2600 18230493083 1000 33000 0 9570 
Guatemala 2009 2600 17441423831 1000 35000 14480297 10500 
Guatemala 2010 2300 18112022315 1000 36000 12885696 11520 
Guatemala 2011 2500 19676313812 1000 38000 14967041 13300 
Guatemala 2012 2600 20665829408 1000 40000 20625980 14800 
Guatemala 2013 2600 21476041475 1000 41000 0 15580 
Guatemala 2014 2700 22884121573 1000 42000 0 15960 
Guatemala 2015 2800 22438026443 1300 44000 0 15840 
Guatemala 2016 2900 0 1600 44000 0 15840 
Honduras 2008 1000 14312310451 1500 24000 15016590 6000 
Honduras 2009 1000 15414152416 1400 23000 13385132 6670 
Honduras 2010 1000 15900027043 1300 23000 15716346 7360 
Honduras 2011 1000 16203737262 1300 22000 15691183 7920 
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Honduras 2012 1000 18370955726 1200 22000 17981687 8800 
Honduras 2013 1000 17589269834 1100 21000 17236972 9030 
Honduras 2014 1000 17254463798 1100 21000 0 9450 
Honduras 2015 1000 17661324708 1000 21000 0 10080 
Honduras 2016 1000 0 1000 21000 0 10710 
India 2008 120000 3799359996 140000 2100000 120000000 210000 
India 2009 110000 3841241243 130000 2000000 120000000 280000 
India 2010 100000 4525077162 120000 2000000 0 380000 
India 2011 99000 4872283264 100000 2000000 0 480000 
India 2012 96000 4905140288 96000 2000000 0 580000 
India 2013 93000 5621882423 88000 2000000 0 720000 
India 2014 89000 5715113981 76000 2000000 0 800000 
India 2015 86000 6331774153 68000 2000000 0 880000 
India 2016 80000 0 62000 2000000 0 980000 
Indonesia 2008 61000 6066673798 16000 430000 29718019 8600 
Indonesia 2009 62000 6390408452 20000 470000 38966576 14100 
Indonesia 2010 61000 10749196512 23000 500000 41224115 20000 
Indonesia 2011 60000 12147174866 26000 530000 42815648 26500 
Indonesia 2012 58000 12447353437 30000 560000 50150781 33600 
Indonesia 2013 56000 12204151855 33000 580000 0 34800 
Indonesia 2014 53000 12007919041 35000 590000 0 47200 
Indonesia 2015 50000 11176174384 37000 600000 0 60000 
Indonesia 2016 48000 0 38000 610000 0 79300 
Kenya 2008 83000 4433673174 86000 1300000 590000000 221000 
Kenya 2009 83000 489815055 74000 1300000 560000000 299000 
Kenya 2010 79000 6191234767 64000 1300000 590000000 377000 
Kenya 2011 77000 5477529974 57000 1300000 600000000 468000 
Kenya 2012 78000 6534393673 49000 1400000 550000000 560000 
Kenya 2013 77000 6985223012 48000 1400000 580000000 588000 
Kenya 2014 73000 7298606376 47000 1400000 0 672000 
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Kenya 2015 66000 7006302021 43000 1400000 0 798000 
Kenya 2016 62000 0 36000 1500000 0 960000 
Lesotho 2008 21000 721477566 10000 240000 35021784 43200 
Lesotho 2009 21000 8277605893 9100 240000 0 57600 
Lesotho 2010 22000 7971178656 8500 250000 0 72500 
Lesotho 2011 21000 10260650736 8100 260000 0 75400 
Lesotho 2012 22000 10252765547 8800 280000 0 86800 
Lesotho 2013 23000 9843654719 9400 290000 0 95700 
Lesotho 2014 22000 10303810473 10000 300000 0 105000 
Lesotho 2015 22000 9085011948 10000 310000 0 124000 
Lesotho 2016 21000 0 9900 310000 0 164300 
Myanmar 2008 18000 1044496719 17000 240000 31276403 14400 
Myanmar 2009 16000 1365033943 17000 230000 32428850 20700 
Myanmar 2010 15000 1533668661 16000 230000 37904167 29900 
Myanmar 2011 14000 1931740944 15000 220000 42349184 37400 
Myanmar 2012 13000 2328002468 14000 220000 0 50600 
Myanmar 2013 13000 2385394437 12000 220000 0 66000 
Myanmar 2014 12000 6239306517 10000 220000 0 83600 
Myanmar 2015 12000 5912304205 8900 220000 0 103400 
Myanmar 2016 11000 0 7800 220000 0 121000 
Niger 2008 2700 2382330835 4800 55000 11893507 2200 
Niger 2009 2400 2326017372 4700 52000 9988336 5720 
Niger 2010 2000 2175313433 4000 51000 14111145 6630 
Niger 2011 2100 2423289025 3900 49000 13635812 8330 
Niger 2012 2100 2350533974 3700 47000 10760854 9870 
Niger 2013 2000 253403301 3400 46000 0 10580 
Niger 2014 2000 2521038814 3200 45000 0 9900 
Niger 2015 2000 2572284735 3400 43000 0 11180 
Niger 2016 1800 0 3400 42000 0 13440 
Sudan 2008 4800 10200115865 1700 35000 14585346 1050 
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Sudan 2009 5100 10565264704 1700 38000 13284928 1900 
Sudan 2010 5100 10385327215 1700 41000 0 2050 
Sudan 2011 5100 11611350068 2000 44000 14477993 2200 
Sudan 2012 5100 953208582 2300 46000 12345112 2300 
Sudan 2013 5100 11773562175 2500 48000 9052243 3360 
Sudan 2014 5000 11080975378 2700 50000 0 4000 
Sudan 2015 5000 15178722854 2900 51000 0 4080 
Sudan 2016 5000 0 3000 53000 0 5300 
Swaziland 2008 13000 20080815852 7700 160000 0 30400 
Swaziland 2009 13000 20952597083 7000 160000 42837711 36800 
Swaziland 2010 13000 31321313673 6500 170000 0 56100 
Swaziland 2011 12000 33043558657 5300 170000 55863617 64600 
Swaziland 2012 12000 28432861506 4800 180000 56115914 79200 
Swaziland 2013 12000 2645405386 4300 190000 63776395 95000 
Swaziland 2014 11000 25253438229 4000 190000 0 114000 
Swaziland 2015 9800 23271534771 3900 200000 0 138000 
Swaziland 2016 8800 0 3900 200000 0 158000 
Ukraine 2008 13000 21565725617 12000 200000 40530098 10000 
Ukraine 2009 13000 168201981 12000 200000 26558619 16000 
Ukraine 2010 16000 18873646253 12000 200000 33877730 22000 
Ukraine 2011 17000 22327625733 11000 200000 0 26000 
Ukraine 2012 17000 26247145977 11000 210000 0 42000 
Ukraine 2013 17000 28187738382 8500 210000 0 54600 
Ukraine 2014 17000 18259447194 7000 220000 0 66000 
Ukraine 2015 17000 12504652052 6700 230000 0 59800 
Ukraine 2016 17000 0 8500 230000 0 85100 
Vietnam 2008 19000 5738314183 9500 210000 100000000 25200 
Vietnam 2009 18000 6261286009 8500 220000 94161904 37400 
Vietnam 2010 17000 7671438475 8600 230000 100000000 48300 
Vietnam 2011 16000 8731325051 9000 230000 73756583 59800 
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Vietnam 2012 15000 1115905283 9100 240000 65119393 72000 
Vietnam 2013 14000 11923131051 9200 240000 0 81600 
Vietnam 2014 13000 11636020296 8900 240000 0 88800 
Vietnam 2015 12000 11673619366 8600 240000 0 103200 
Vietnam 2016 11000 0 8000 240000 0 112800 
Zambia 2008 69000 5576964 43000 830000 0 199200 
Zambia 2009 68000 4902904194 35000 860000 0 249400 
Zambia 2010 67000 6736954123 29000 900000 0 306000 
Zambia 2011 68000 7930013119 27000 940000 0 376000 
Zambia 2012 67000 8161532371 25000 970000 260000000 426800 
Zambia 2013 68000 8988045063 24000 1000000 0 500000 
Zambia 2014 68000 8709195162 22000 1100000 0 605000 
Zambia 2015 62000 6936708094 22000 1100000 0 704000 
Zambia 2016 59000 0 21000 1100000 0 715000 
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Argentina 2008 5300 56732801042 2000 93000 6482770 47430 
Argentina 2009 5300 57681118144 2000 96000 728886 50880 
Argentina 2010 5300 69860349564 2000 99000 0 54450 
Argentina 2011 5300 80685994946 2100 100000 0 56000 
Argentina 2012 5300 86450535407 2200 100000 0 58000 
Argentina 2013 5400 92081287954 2200 110000 0 66000 
Argentina 2014 5400 84505468735 2300 110000 0 67100 
Argentina 2015 5400 99793137533 2400 110000 0 69300 
Argentina 2016 5500 0 2400 120000 0 76800 
Botswana 2008 13000 32145602757 8000 290000 110000000 107300 
Botswana 2009 13000 34981400746 6600 290000 86185023 127600 
Botswana 2010 13000 38096642295 5800 300000 100000000 150000 
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Botswana 2011 13000 47145818324 5600 310000 91393937 167400 
Botswana 2012 13000 49865686686 5100 320000 0 195200 
Botswana 2013 13000 37802302445 4800 330000 0 214500 
Botswana 2014 12000 39757059237 4500 330000 0 231000 
Botswana 2015 11000 38937098204 4200 340000 0 261800 
Botswana 2016 10000 0 3900 350000 0 290500 
Brazil 2008 47000 70490575712 14000 570000 6252947 188100 
Brazil 2009 46000 71996152713 15000 600000 3303385 210000 
Brazil 2010 47000 89494141894 14000 630000 9171381 239400 
Brazil 2011 47000 102931139719 14000 660000 9743606 264000 
Brazil 2012 47000 96078378041 14000 690000 9258557 296700 
Brazil 2013 48000 97593540495 14000 720000 0 338400 
Brazil 2014 48000 101409210495 14000 750000 0 382500 
Brazil 2015 48000 78039598216 14000 790000 0 450300 
Brazil 2016 48000 0 14000 820000 0 492000 
Columbia 2008 6800 32764064874 5000 110000 501306 13200 
Columbia 2009 6900 32912683771 5900 110000 220541 15400 
Columbia 2010 6900 38404702232 6600 110000 275591 33000 
Columbia 2011 6800 42947240213 5800 110000 0 30800 
Columbia 2012 6500 48117888515 4600 110000 176131 36300 
Columbia 2013 6300 48296442417 4000 120000 30602 46800 
Columbia 2014 6100 50667599133 3600 120000 0 54000 
Columbia 2015 5800 37423638765 3200 120000 0 63600 
Columbia 2016 5600 0 2800 120000 0 0 
Dominican Republic 2008 3200 23367806801 5500 78000 15269296 10920 
Dominican Republic 2009 3000 25035341801 4900 76000 0 12920 
Dominican Republic 2010 2700 29965610197 4400 73000 0 16060 
Dominican Republic 2011 2700 32662454505 4100 71000 0 19170 
Dominican Republic 2012 2700 35153943987 3700 69000 20711558 21390 
Dominican Republic 2013 2700 356898662 3400 68000 0 23120 
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Dominican Republic 2014 2700 37664217244 3100 67000 0 26130 
Dominican Republic 2015 2600 39669252242 2700 66000 0 30360 
Dominican Republic 2016 2500 0 2200 65000 0 29900 
Gabon 2008 2700 25762783925 3100 47000 1488301 7050 
Gabon 2009 2500 26339789445 3100 46000 2543529 9200 
Gabon 2010 2500 21671412151 2900 45000 2356058 9900 
Gabon 2011 2500 27408999726 2900 45000 3604203 11700 
Gabon 2012 2400 23663051177 2600 44000 2003421 13640 
Gabon 2013 2300 27498907252 2200 44000 0 18040 
Gabon 2014 2100 24548532796 1800 44000 0 19800 
Gabon 2015 2000 19794471527 1700 44000 0 24640 
Gabon 2016 1700 0 1500 45000 0 28350 
Iran, Islamic Rep. 2008 6600 29943993154 2700 58000 4462550 1160 
Iran, Islamic Rep. 2009 6300 36757558237 3000 61000 4551488 1220 
Iran, Islamic Rep. 2010 5800 4408524948 3300 62000 0 2480 
Iran, Islamic Rep. 2011 5600 52469162232 3600 63000 0 2520 
Iran, Islamic Rep. 2012 5500 51930359483 3800 64000 0 3840 
Iran, Islamic Rep. 2013 5400 41372777441 3900 64000 0 4480 
Iran, Islamic Rep. 2014 5300 38270589533 4000 65000 0 5850 
Iran, Islamic Rep. 2015 5100 36598222838 4000 65000 0 7150 
Iran, Islamic Rep. 2016 5000 0 4000 65000 0 9100 
Malaysia 2008 10000 27257975556 8500 110000 291 9900 
Malaysia 2009 9500 259071191 8500 110000 447059 11000 
Malaysia 2010 8700 30201106452 8500 110000 56188 13200 
Malaysia 2011 8200 361538638 8500 110000 2396941 14300 
Malaysia 2012 7600 39127214373 8400 110000 1665338 15400 
Malaysia 2013 7000 400 8500 100000 2105998 16000 
Malaysia 2014 6500 43505859405 8300 100000 0 21000 
Malaysia 2015 5800 3856203588 7800 99000 0 25740 
Malaysia 2016 5700 0 7000 96000 0 35520 
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Mexico 2008 12000 55653465799 5200 170000 1617983 52700 
Mexico 2009 12000 47764885047 5100 170000 1379026 56100 
Mexico 2010 12000 53874476692 5400 180000 0 64800 
Mexico 2011 12000 56512919162 5700 190000 12168390 72200 
Mexico 2012 12000 58074840706 5700 190000 0 81700 
Mexico 2013 12000 61787469815 5000 200000 0 90000 
Mexico 2014 12000 59339844837 4900 200000 0 94000 
Mexico 2015 12000 53481092964 4800 210000 0 115500 
Mexico 2016 12000 0 4200 220000 0 132000 
Namibia 2008 11000 39703713766 5700 170000 0 51000 
Namibia 2009 12000 34096818147 4900 180000 120000000 59400 
Namibia 2010 12000 49150411028 4800 180000 110000000 77400 
Namibia 2011 11000 54415338972 4200 190000 0 96900 
Namibia 2012 11000 52833319309 3800 200000 0 110000 
Namibia 2013 11000 47403643795 3600 200000 0 116000 
Namibia 2014 10000 44244143541 3700 210000 0 123900 
Namibia 2015 10000 42307045216 4300 210000 0 132300 
Namibia 2016 9600 0 4300 220000 0 140800 
Papua New Guinea 2008 2800 3671631442 1700 35000 0 4550 
Papua New Guinea 2009 2700 3895797768 1600 36000 40132667 5760 
Papua New Guinea 2010 2700 4225284029 1700 37000 38821670 7030 
Papua New Guinea 2011 2700 5675515326 1700 37000 34509487 8510 
Papua New Guinea 2012 2700 761627761 1700 38000 29533509 11020 
Papua New Guinea 2013 2700 9897123206 1500 39000 0 13650 
Papua New Guinea 2014 2700 9755258656 1300 40000 0 16800 
Papua New Guinea 2015 2800 7734963166 1200 41000 0 19680 
Papua New Guinea 2016 2800 0 1100 42000 0 21840 
Rwanda 2008 8500 4731350709 7700 180000 100000000 59400 
Rwanda 2009 9200 5130129532 6700 180000 160000000 72000 
Rwanda 2010 9800 5500867604 5600 180000 0 84600 
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Rwanda 2011 8800 5842114233 4600 190000 220000000 98800 
Rwanda 2012 9200 6004236447 4000 190000 220000000 114000 
Rwanda 2013 8000 567600488 3700 200000 0 130000 
Rwanda 2014 7700 5930431056 3500 200000 0 136000 
Rwanda 2015 7700 5665848825 3400 200000 0 148000 
Rwanda 2016 7500 0 3300 210000 0 168000 
Thailand 2008 15000 15147379322 27000 510000 30508991 163200 
Thailand 2009 14000 15245145335 25000 500000 13986791 180000 
Thailand 2010 13000 17205752988 23000 500000 35926668 205000 
Thailand 2011 12000 195938433 21000 490000 46430392 220500 
Thailand 2012 11000 20644031739 20000 480000 0 235200 
Thailand 2013 9700 21300305772 19000 470000 0 249100 
Thailand 2014 8700 21936612675 18000 460000 0 266800 
Thailand 2015 7300 21713523195 16000 450000 0 274500 
Thailand 2016 6400 0 16000 440000 0 303600 
Venezuela, RB 2008 7100 49505768162 1900 85000 156014 27200 
Venezuela, RB 2009 7100 5904493596 2000 90000 345384 32400 
Venezuela, RB 2010 7000 61411194936 2000 95000 626411 38950 
Venezuela, RB 2011 7000 520 1900 99000 133327 40590 
Venezuela, RB 2012 7000 47419447582 2100 100000 702563 42000 
Venezuela, RB 2013 6900 42987161149 2400 110000 817796 44000 
Venezuela, RB 2014 6800 56950042522 2900 110000 0 42900 
Venezuela, RB 2015 6600 97295147312 3300 110000 0 60500 
Venezuela, RB 2016 6500 0 2500 120000 0 73200 
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Pakistan 2008 13000 2698818286 1000 42000 4476514 840 
Pakistan 2009 14000 2532489896 1000 54000 8261902 1080 
Pakistan 2010 14000 265686252 1300 65000 8163974 1950 
Pakistan 2011 14000 2864483945 1900 75000 2181908 2250 
Pakistan 2012 15000 2846501237 2600 86000 6992470 3440 
Pakistan 2013 16000 3155068096 3300 97000 6361662 2910 
Pakistan 2014 17000 3652147697 4100 110000 0 5500 
Pakistan 2015 18000 3799237688 4800 120000 0 6000 
Pakistan 2016 19000 0 5500 130000 0 9100 
Senegal 2008 2500 470301365 1600 41000 19177943 8610 
Senegal 2009 2000 4246641606 1500 41000 0 9840 
Senegal 2010 1800 4013842343 1500 40000 0 11200 
Senegal 2011 1600 4268439656 1700 40000 19809176 12000 
Senegal 2012 1500 396913484 1800 39000 0 11310 
Senegal 2013 1300 4074475539 2000 38000 0 12540 
Senegal 2014 1400 4197709433 2100 37000 0 14430 
Senegal 2015 1200 3607884461 2000 37000 0 16280 
Senegal 2016 1100 0 1900 36000 0 18720 
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